Incyte (INCY) Prepaid Assets (2010 - 2026)
Incyte's (INCY) quarterly Prepaid Assets came in at $253.1 million in Q2 2026, down 14.4% YoY from $295.6 million in Q2 2025, and down 16.01% on a QoQ basis from $301.3 million in Q1 2026.
Incyte (INCY) Prepaid Assets (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Prepaid Assets data on file, last reported at $253.1 million in Q2 2026.
- Quarterly Prepaid Assets fell 14.4% year-over-year to $253.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $253.1 million (down 14.4% YoY) and the FY2025 annual result came in at $317.8 million, up 88.16% from the prior year.
- Prepaid Assets eased to $253.1 million in Q2 2026, from $301.3 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $368.7 million in Q3 2025 to a low of $146.1 million in Q1 2022.
- A 5-year average of $216.4 million and a median of $191.7 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets surged 98.76% — and 2026, when it decreased 14.4%.
- Tracing INCY's Prepaid Assets over 5 years: stood at $167.0 million in 2022, then grew by 9.47% to $182.8 million in 2023, then retreated by 7.61% to $168.9 million in 2024, then jumped by 88.16% to $317.8 million in 2025, then slipped by 20.37% to $253.1 million in 2026.
- The last three Prepaid Assets figures came in at $253.1 million (Q2 2026), $301.3 million (Q1 2026), and $317.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.09 Mn |
| Mar 31, 2026 | 301.31 Mn |
| Dec 31, 2025 | 317.83 Mn |
| Sep 30, 2025 | 368.73 Mn |
| Jun 30, 2025 | 295.65 Mn |
| Mar 31, 2025 | 211.65 Mn |
| Dec 31, 2024 | 168.91 Mn |
| Sep 30, 2024 | 205.13 Mn |
| Jun 30, 2024 | 207.96 Mn |
| Mar 31, 2024 | 189.24 Mn |
| Dec 31, 2023 | 182.83 Mn |
| Sep 30, 2023 | 171.75 Mn |
| Jun 30, 2023 | 167.14 Mn |
| Mar 31, 2023 | 194.26 Mn |
| Dec 31, 2022 | 167.01 Mn |
| Sep 30, 2022 | 179.93 Mn |
| Jun 30, 2022 | 165.95 Mn |
| Mar 31, 2022 | 146.13 Mn |
| Dec 31, 2021 | 126.28 Mn |
| Sep 30, 2021 | 101.73 Mn |